-
Bolsonaro faces criticism for his handling of the pandemic, which has included playing down the virus, opposing lockdown measures.
-
According to the RDIF -- Russia's sovereign wealth fund, the vaccine's interim clinical trial results show 95 per cent efficacy on the 42nd day after the first dose.
-
Modi will be arriving at Hakimpet Air Force station in an IAF flight from Pune in the afternoon, an official memo issued by the Telangana Chief Secretary on Thursday night said.
-
The Hyderabad-based firm, while applying for phase-three trial, stated that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported.
-
Hyderabad-headquartered biologicals company setting up new viral antigen plant at Karkapatla in Telangana to cater to viral vaccines and opens new sterile filling facility
-
Latest figures on Tuesday showed that the country had recorded a total of 259,600 Covid deaths and 12.5 million cases -- with over 2,000 deaths and 167,000 new cases in just the last 24 hours.
-
The Oxford-AstraZeneca vaccine is being made in partnership with Serum Institute.
-
A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials, the team reported Monday.
-
In the new study, published in The Journal of Clinical Investigation, the research team tested the blood of more than 6,000 healthcare workers for evidence of antibodies to SARS-CoV-2.
-
The Covid-19 pandemic has infected more than 55 million people and caused more than 1.3 million deaths worldwide.
-
He had offered to be the first volunteer for the third phase trial of Covaxin, which started in the state today.
-
The scientific head of the US operation to develop a vaccine, Moncef Slaoui said Monday that the green light would probably come in December.
-
"Very likely by the summer, a lot of things will be back to normal... If vaccine approvals come along quickly," Gates said in a television interview on Thursday night.
-
The study, published in The Lancet medical journal, suggest that those aged over 70 -- who are at higher risk of serious illness and death from Covid-19 -- could build robust immunity to the novel Coronavirus.
-
The team is also testing whether the vaccine stops people developing COVID-19 in larger Phase 3 trials and early results from this crucial stage are expected in the coming weeks.
-
Global drugmakers Pfizer and BioNTech said on Wednesday that their COVID-19 vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial.
-
Bharat Biotech had on Monday said the Phase 3 trial of Covaxin will involve 26,000 volunteers across 25 centres in India and is being conducted in partnership with the ICMR.
-
Developments on vaccine front offer a tentative timeline on when it could be available on a mass scale
-
Tata Steel was the top gainer in the Sensex pack, rising over 4 per cent, followed by Bharti Airtel, SBI, HDFC Bank, M&M, Asian Paints and Reliance Industries.
-
Moderna, whose results stem from a clinical trial of more than 30,000 participants, expects to have approximately 20 million doses ready to ship in the United States by year-end.